Exceptional Potential
Exceptional Value
Exceptionally Risky
Recent Posts


Jan 22, 2016 @ 3:00pm $6.56


At least it appears to.  The evidence that their system for attacking liver cancer is very compelling.  See their site http://delcath.com/chemotherapy/


Delcath will soon prove, or fail to prove, to the FDA that their technology for treating liver cancer is safe and effective.  If they are successful, I expect Delcath will have very substantial growth in their revenues, earnings and their stock price.  I am very optimistic.  The risks are high, if they fail, so will their stock’s price.